Low Level Laser Therapy Impact on Cognitive Function and Quality of Life in Alzheimer Anemic Elderly Patients

Sponsor
Cairo University (Other)
Overall Status
Completed
CT.gov ID
NCT04496778
Collaborator
(none)
60
1
2
6.9
8.7

Study Details

Study Description

Brief Summary

Alzheimer's is a type of dementia that affects memory, thinking and behavior. Symptoms eventually grow severe enough to interfere with daily tasks. this study aimed to delay the deterioration of anemic elderly condition as memory affection interfere with daily life activities and social interaction

Condition or Disease Intervention/Treatment Phase
  • Device: low level laser therapy ( laser acupuncture combined with nasal laser irradiation)
  • Other: aerobic exercise
N/A

Detailed Description

Alzheimer's disease is the commonest cause of dementia and describes a clinical syndrome made up of three domains. First, a neuro-psychological domain encompassing those deficits of cognitive function such as amnesia (memory loss), aphasia (language disturbance), apraxia (the inability to carry out motor tasks despite intact motor functions) and agnosia (the inability to recognize people or objects despite intact sensory functions). Second, a group of psychiatric symptoms and behavioral disturbances, which have been termed neuro-psychiatric features, non-cognitive phenomena, or behavioral and psychological symptoms of dementia Alzheimer's disease is substantially increased among people aged 65 years or more, with a progressive decline in memory, thinking, language and learning capacity. Alzheimer's disease should be differentiated from normal age-related decline in cognitive function, which is more gradual and associated with less disability. Diabetes, hypertension, smoking, obesity, and dyslipidemia have all been found to increase risk as well a history of brain trauma, cerebrovascular disease, and vasculopathies.

Dementia affects approximately 5%-8% of individuals over age 65, 15%- 20% of individuals over age 75, and 25%-50% of individuals over age 85. Alzheimer disease is the most common dementia, accounting for 50%-75% of the total, with a greater proportion in the higher age ranges Dementia is expensive. The financial costs of managing Alzheimer's disease are enormous. The cost of illness is high in terms of both public and private resources. Families and caregivers who are required to provide care and patients affected by dementia also pay a high price in terms of their quality of life The primary goals of treatment are to maximize the patient's ability to function in daily life, maintain quality of life, slow the progression of symptoms, and treat depression or disruptive behaviors Low level laser therapy is a safe, non-invasive, and non-thermal modality that is based on a strong body of research dating back to the 1960.It involved in treating several conditions, the mechanisms of action involve the stimulation of mitochondria by the absorption of photons in cytochrome c oxidase, resulting in increased adenosine triphosphate production, reduced oxidative stress, anti-inflammatory effects, and increased focal cerebral blood flow

Study Design

Study Type:
Interventional
Actual Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
The Beneficial Effect of Low Level Laser Therapy Combined With Nasal Irradiation on Cognitive Function and Quality of Life in Alzheimer Anemic Elderly Patients
Actual Study Start Date :
Jan 3, 2020
Actual Primary Completion Date :
Jul 28, 2020
Actual Study Completion Date :
Aug 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: low level laser plus exercise

acupuncture low level laser combined with nasal laser irradiation in addition to aerobic exercise 3 times per week for 3 months

Device: low level laser therapy ( laser acupuncture combined with nasal laser irradiation)
Cold Laser Therapy Watch (Laser Watch- 650 nm) combines acupuncture and nasal cavity for external blood irradiation. Laser watch with 10 laser beams - is applied to the left wrist. Nasal Probe with 2 laser beams - is applied to the nose cavity

Other: aerobic exercise
3 d/week for 45 to 60 minutes per session for 3 months. started by 40%-50% Heart Rate Reserve (determined by using a walking treadmill exercise test) during the first 6 weeks increasing gradually up to 50%-70% Heart Rate Reserve

Placebo Comparator: sham laser plus exercise

placebo acupuncture low level laser combined with nasal laser irradiation in addition to aerobic exercise 3 times per week for 3 months

Device: low level laser therapy ( laser acupuncture combined with nasal laser irradiation)
Cold Laser Therapy Watch (Laser Watch- 650 nm) combines acupuncture and nasal cavity for external blood irradiation. Laser watch with 10 laser beams - is applied to the left wrist. Nasal Probe with 2 laser beams - is applied to the nose cavity

Other: aerobic exercise
3 d/week for 45 to 60 minutes per session for 3 months. started by 40%-50% Heart Rate Reserve (determined by using a walking treadmill exercise test) during the first 6 weeks increasing gradually up to 50%-70% Heart Rate Reserve

Outcome Measures

Primary Outcome Measures

  1. change of cognitive function [3 months]

    comparison of Montreal assessment scale scores before and after the intervention It range between 0 and 30. A score of 26 or over is considered to be normal.

  2. changes of hemoglobin level [3 months]

    comparison of hemoglobin level for those anemic elderly before and after the intervention

  3. changes of balance [3 months]

    comparison of berg balance scale scores before and after the intervention. It is a 14 item list with each item consisting of a five-point ordinal scale ranging from 0 to 4, with 0 indicating the lowest level of function and 4 the highest level of function

  4. changes of quality of life [3 months]

    comparison of quality of life for Alzheimer disease scores before and after the intervention. It comprised of 13 items (physical health, energy, mood, living situation, memory, family, marriage, friends, self as a whole, ability to do chores, ability to do things for fun, money and life as a whole) for a total score of 13-52 with higher scores indicating better quality of life

Secondary Outcome Measures

  1. changes of body mass index [3 months]

    comparison of body weight (kilogram) before and after the study in relation to height per meter square (weight and height will be combined to report BMI in kg/m^2)

  2. changes of waist hip ratio [3 months]

    changes of waist hip ratio before and after the study

Eligibility Criteria

Criteria

Ages Eligible for Study:
65 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Sixty elderly patients aged from 65-75 y

  • Body mass index (BMI) ranged from 30 to 34.9 kg/m2

  • Mild cognitive dysfunction (Montreal cognitive assessment scores from 19-25

  • Anemic

  • The time between their diagnoses and participation in the study ranged from 6 months to 2 years

Exclusion Criteria:
  • Moderate to severe cognitive impairment

  • History of neurological disease ,stroke or Cardiovascular disease

  • History of nasal bleeding or fracture

  • Known photo-sensitivity disorder

  • Current active cancer or within one year of cancer treatment or remission

  • Serious mental health illness that in the opinion of the investigator would preclude the subject from study participation

  • Active infection, wound or other external trauma to the target area to receive the laser therapy

  • Participation in a clinical study or other type of research in the past 30 days

Contacts and Locations

Locations

Site City State Country Postal Code
1 Cairo Giza Dokki Egypt 11432

Sponsors and Collaborators

  • Cairo University

Investigators

  • Principal Investigator: Ebtesam Nabil, doctoral, Cairo University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ebtesam Nabil, principal investigator, Cairo University
ClinicalTrials.gov Identifier:
NCT04496778
Other Study ID Numbers:
  • P.T.REC/012/0027772
First Posted:
Aug 3, 2020
Last Update Posted:
Aug 25, 2020
Last Verified:
Aug 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Ebtesam Nabil, principal investigator, Cairo University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 25, 2020